Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Daneshmand on Emerging Treatments in Bladder Cancer

May 26th 2022

Sia Daneshmand MD, discusses emerging treatments in bladder cancer.

Front-Line Lenvatinib + Pembrolizumab Combination Regimens for Advanced RCC: Selecting Patients and Dose

May 25th 2022

A review of the first-line IO-TKI combination regimens available for advanced RCC and selecting the right patients and dose for treatment with Lenvatinib + pembrolizumab.

Patient Profile Presentation: A 56-Year-Old Man with Metastatic Clear Cell RCC

May 25th 2022

Robert Alter, MD, presents the patient profile of a 56-year-old man with metastatic clear cell renal cell carcinoma presenting with chromaturia.

Nivolumab Plus Axitinib Generates Promising Responses in Untreated Advanced RCC

May 24th 2022

The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.

Kevin Hakimi on the Rationale of the PADRES Trial in RCC

May 24th 2022

Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.

Unmet Needs and Future Perspectives in Advanced RCC

May 18th 2022

The panel concludes with final thoughts on unmet needs and future perspectives for the treatment of advanced clear-cell RCC.

Is There a Role for Cabozantinib in the First-Line Setting in Advanced RCC in Certain Populations?

May 18th 2022

Dr Bilen discusses the potential use of cabozantinib as a first-line therapy in patients who receive immunotherapy in the adjuvant setting.

Sequencing Therapies in the Second Line and Beyond in Advanced RCC

May 18th 2022

Dr Barata comments on sequencing therapies in the second line and beyond in patients with advanced RCC.

Dr. Ornstein on Unmet Needs in Refractory RCC

May 17th 2022

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.

Dr. Fleming on the KEYNOTE-426 Trial in Metastatic RCC

May 17th 2022

Mark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.

Pal Discusses Eye-Catching ASCO GU Data in RCC

May 16th 2022

Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab plus axitinib for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.

Neoadjuvant Axitinib Effective in Subgroup of Patients with Renal Cell Carcinoma

May 16th 2022

Neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

Dr. Spiess on Key Updates in the Management of Penile Cancer

May 15th 2022

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

Dr. Vaishampayan on the Design of the PROBE Trial in RCC

May 13th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.

Cabozantinib Plus Nivolumab Shows Efficacy in Papillary Non–Clear Cell RCC

May 11th 2022

The combination of cabozantinib plus nivolumab demonstrated promising objective response rates in patients with non–clear cell renal cell carcinoma with prominent papillary features.

Treatment Options in the Second-Line and Beyond in Advanced RCC

May 11th 2022

Drs Zhang and Ornstein discuss regimens for advanced clear-cell RCC in the second-line setting and beyond, focusing on the METEOR, CABOSEQ,TIVO-3 CHeckMate 025, and AXIS trials.

The Impact of Neoadjuvant Therapy on Treatment Selection in Advanced RCC

May 11th 2022

Dr Ornstein describes how the choice of neoadjuvant therapy can impact subsequent treatment selection in advanced RCC.

ARO-HIF2 Lowers HIF2α Expression and Demonstrates Favorable Safety Profile in Clear Cell RCC

May 4th 2022

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.

The Future of Advanced Renal Cell Carcinoma Management

May 4th 2022

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Using Cabozantinib + Nivolumab to Treat Advanced Renal Cell Carcinoma

May 4th 2022

A discussion on the use of cabozantinib-nivolumab for the treatment of advanced renal cell carcinoma.